Parkman Healthcare Partners LLC Has $6.97 Million Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Parkman Healthcare Partners LLC boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 526,973 shares of the company’s stock after acquiring an additional 18,690 shares during the period. Parkman Healthcare Partners LLC owned approximately 0.62% of Syndax Pharmaceuticals worth $6,967,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Virtus ETF Advisers LLC grew its stake in shares of Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after purchasing an additional 827 shares during the period. E Fund Management Co. Ltd. grew its stake in shares of Syndax Pharmaceuticals by 14.4% in the 4th quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company’s stock valued at $167,000 after purchasing an additional 1,583 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Syndax Pharmaceuticals by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company’s stock valued at $239,000 after purchasing an additional 1,732 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Syndax Pharmaceuticals by 3.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,748 shares of the company’s stock valued at $706,000 after purchasing an additional 1,811 shares during the period. Finally, R Squared Ltd bought a new stake in shares of Syndax Pharmaceuticals in the 4th quarter valued at approximately $26,000.

Syndax Pharmaceuticals Stock Performance

NASDAQ:SNDX opened at $10.19 on Wednesday. The stock’s fifty day moving average price is $12.41 and its two-hundred day moving average price is $14.30. Syndax Pharmaceuticals, Inc. has a 52-week low of $9.66 and a 52-week high of $25.07. The company has a market cap of $876.82 million, a price-to-earnings ratio of -2.81 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.06. The firm had revenue of $20.04 million for the quarter, compared to analyst estimates of $15.88 million. During the same period in the prior year, the company posted ($0.85) EPS. The firm’s quarterly revenue was up 1900.0% compared to the same quarter last year. On average, equities analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SNDX shares. JPMorgan Chase & Co. upped their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 20th. Citigroup lowered their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Scotiabank boosted their target price on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a “sector perform” rating in a report on Tuesday, May 6th. StockNews.com raised Syndax Pharmaceuticals to a “sell” rating in a report on Tuesday, May 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.91.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).